A Phase 2a, Randomized, Open-Label, Active Control, Multi-Center Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients
Location: CPMC (San Francisco)
Please contact: Clinicalresearch@sutterhealth.org about Study Astellas FSGSView study details on ClinicalTrials.gov
Patients at least 18years old who has a biopsy-proven, pFSGS as a cause of ESRD in their native kidneys are eligible for the study. Patients who previously received an organ transplant and patients who will be receiving multi-organ or dual kidney transplants are not eligible for the study.
Status: Active and open to enrollment.
June 01, 2018